Breakthrough in Colon Cancer Treatment: Dual PD-1/CTLA-4 Blockade Show Superior Progression-Free Survival

Strategic Insights -

Researchers from the IRCCS Foundation National Cancer Institute in Milan, Italy, have published a study in The Oncologist, a leading oncology journal, highlighting the superiority of dual PD-1/CTLA-4 blockade with nivolumab and ipilimumab in treating metastatic colorectal cancer (mCRC) patients with deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H). This study is a significant advancement in the field of oncology, offering new hope for patients with this aggressive form of cancer.

Key Takeaways:

  • The international multicenter study included 711 patients with dMMR/MSI-H mCRC receiving either chemotherapy with or without biologics, anti-PD-1 monotherapy, or dual PD-1/CTLA-4 blockade as a first-line treatment.
  • The dual PD-1/CTLA-4 blockade demonstrated superior progression-free survival (PFS) compared to chemotherapy and anti-PD-1 monotherapy, with a hazard ratio (HR) of 0.14 and P value <0.001.
  • The prognostic impact of several clinical features, such as age, sex, and tumor stage, did not seem to be retained in patients treated upfront with ICIs combination, suggesting that these factors may not be relevant in the context of combination therapy.
  • The study was funded by AstraZeneca, and the research was conducted by a team of experts from the IRCCS Foundation National Cancer Institute, including Filippo Pietrantonio, Vincenzo Nasca, and Chiara Cremolini.
  • The study's findings have significant implications for the treatment of dMMR/MSI-H mCRC, highlighting the potential of dual PD-1/CTLA-4 blockade as a first-line treatment option.

Statistics:

  • Among 711 patients, 51.2% received chemotherapy with or without biologics, 37.1% anti-PD-1 monotherapy, and 11.7% dual PD-1/CTLA-4 blockade.
  • The dual PD-1/CTLA-4 blockade showed a significant improvement in PFS compared to chemotherapy and anti-PD-1 monotherapy, with a hazard ratio (HR) of 0.14 and P value <0.001.
  • The study's results were consistent with previous published data across treatment lines, suggesting that the prognostic impact of several clinical features may not be relevant in the context of combination therapy.

Sources:

  • First-line Pd-1+/- Ctla-4 Blockade In Patients With Deficient Mismatch Repair And/or Microsatellite Instability-high Metastatic Colorectal Cancer. The Oncologist, 2025;30(9).
  • Researchers at IRCCS Foundation National Cancer Institute Release New Data on Colon Cancer (First-line Pd-1+/- Ctla-4 Blockade In Patients With Deficient Mismatch Repair And/or Microsatellite Instability-high Metastatic Colorectal Cancer). Cancer Weekly. October 21, 2025; p 1432.